Silas Inman

The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.

Treatment with the investigational oral agent TAS-102 significantly improved overall survival in a phase III trial for patients with heavily pretreated metastatic colorectal cancer.

The combination of the BRAF inhibitor vemurafenib with the investigational MEK inhibitor cobimetinib was safe and effective in treatment-naive patients with BRAFV600 mutation-positive metastatic melanoma.

The FDA has assigned a priority review designation to the PD-1 inhibitor pembrolizumab (MK-3475) as a treatment for patients with unresectable or metastatic melanoma following progression on ipilimumab.

The FDA has approved subcutaneous omacetaxine mepesuccinate injection for home administration in patients with chronic or accelerated phase CML who are resistant or intolerant to treatment with TKIs.

The addition of the investigational agent MM-398 (PEP02) to standard second-line chemotherapy significantly improved overall survival in a phase III trial for patients with metastatic pancreatic cancer.

The FDA has approved the next-generation ALK inhibitor ceritinib as a treatment for ALK-positive patients with metastatic non-small cell lung cancer following treatment with crizotinib.

The combination of custirsen (OGX-011) with docetaxel and prednisone failed to significantly extend survival as a first-line treatment for men with metastatic castration-resistant prostate cancer

The FDA has approved the cobas HPV Test as a first-line screening tool for cervical cancer in women 25 and older, making it the first-ever approval for a diagnostic alternative to Pap smear.

The FDA has approved the anti-IL-6 chimeric monoclonal antibody siltuximab as a treatment for HIV- and HHV-8-negative patients with multicentric Castleman's disease.

GSK and Novartis have struck a deal that will move all of GSK's oncology assets to Novartis, all of Novartis' non-flu-related vaccines to GSK, and will result in a joint consumer healthcare venture.

The FDA has approved the VEGFR-2 inhibitor ramucirumab as a treatment for patients with patients with unresectable gastric cancer or gastroesophageal junction adenocarcinoma, based on a significant extension in OS.

Talimogene laherparepvec significantly improved durable response rates but failed to extend overall survival in patients with advanced melanoma.

The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.

A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.

The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.

The combination of palbociclib and letrozole more than doubled PFS and showed a non–statistically significant 4.2-month improvement in OS for patients with ER-positive, HER2-negative metastatic breast cancer.

The CDK4/6 inhibitor LY2835219 demonstrated promising single-agent activity in heavily pretreated patients with HR-positive metastatic breast cancer.

The large phase III MAGRIT study investigating the MAGE-A3-specific vaccine GSK1572932A for patients with non-small cell lung cancer (NSCLC) will be completely halted following an interim analysis that demonstrated a lack of benefit.

The next-generation EGFR inhibitor CO-1686 has demonstrated promising activity in T790M-positive patients with non-small cell lung cancer.

The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA's Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test's benefits outweigh its risks

The MAGE-A3-specific immunotherapeutic GSK1572932A failed to significantly extend disease-free survival (DFS) in patients with resected nonmetastatic non-small cell lung cancer (NSCLC) who tested negative for a specific gene expression signature

The oncolytic immunotherapeutic vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage in 64% of patients with advanced melanoma, including a marked reduction in the size of uninjected metastatic lesions

The FDA has placed a full clinical hold on the development of the investigational telomerase inhibitor imetelstat following concerns over consistent low-grade liver function test (LFT) abnormalities

The first-line combination of trastuzumab and eribulin mesylate demonstrated an ORR of 71.2% with a median PFS of 11.6 months in patients with HER2-positive advanced breast cancer.

The most promising novel therapeutics in development for patients with breast cancer focus primarily on targeting activating mutations in combinations that are based on findings from next-generation sequencing.

A phase III study exploring the MET inhibitor onartuzumab as a treatment for patients with NSCLC is being stopped, following an interim analysis that suggested a lack of clinically meaningful efficacy.

The FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia who have received at least one previous therapy.

The FDA has granted a priority review designation to the intravenous pan-HDAC inhibitor belinostat (Beleodaq) as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma

Eltrombopag has received a Breakthrough Therapy designation from the FDA for the treatment of cytopenias in patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy.